Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 24, 2023, titled "Zydus receivesfinal approval from the USFDA for Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg".
Press Release Feb 24 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Pitavastatin Tablets in various strengths. The approval allows Zydus to manufacture the drug at its facility in Moraiya, which is indicated for managing cholesterol levels in patients. The press release highlights that Pitavastatin had significant annual sales in the United States, indicating its market potential.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 20 2023
- Press Release Feb 17 2023
- Press Release Feb 15 2023
- Press Release Jan 27 2023
- Press Release Jan 16 2023
Later from Zydus Lifesciences
- Press Release Feb 28 2023
- Press Release Mar 02 2023
- Press Release Mar 03 2023
- Press Release Mar 07 2023
- Press Release Mar 09 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences